SAVARA INC.
DUNS: 801937272
# of Employees: 6
HUBZone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Award Charts
Award Listing
-
Record 1 TO 4
-
Targeted nanoparticle gene therapy for lung cancer
Amount: $190,353.00DESCRIPTION (provided by applicant): Project Summary A transformational NanoNucleic delivery technology is being investigated by Savara Inc. as a promising first-in-class gene therapy candidate for lu ...
SBIRPhase I2013Department of Health and Human Services -
Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF
Amount: $3,986,098.00DESCRIPTION provided by applicant Persistent respiratory methicillin resistant Staphylococcus aureus MRSA infections have become increasingly common in cystic fibrosis CF patients with a prev ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
Development of Inhaled Vancomycin for Treatment of MRSA Infections in CF
Amount: $149,750.00DESCRIPTION (provided by applicant): Savara Inc. is developing a novel inhaled dry-powder form of vancomycin (AEROVANC) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infectio ...
SBIRPhase I2012Department of Health and Human Services -
A High Efficiency Corticosteroid Dry Powder Inhaler for Pediatric Use
Amount: $184,148.00DESCRIPTION (provided by applicant): Asthma is a chronic respiratory disease with a global human and economic burden on patients, and society. Asthma treatment mainly consists of inhaled corticosteroi ...
SBIRPhase I2011Department of Health and Human Services
